These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
NEVADA
|
80-0651816
|
|
(State or other jurisdiction of incorporation or organization)
|
(IRS Employer Identification No.)
|
|
6312 Seven Corners Center, # 303
|
|
|
Falls Church, Virginia
|
22044
|
|
(Address of principal executive offices)
|
(Zip Code)
|
|
Title of each class registered:
|
Name of each exchange on which registered:
|
|
None
|
None
|
|
Large accelerated filer
|
o
|
Accelerated filer
|
o
|
|
Non-accelerated filer
|
o
|
Smaller reporting company
|
x
|
|
(Do not check if a smaller reporting company)
|
|
PAGE
|
||||
|
PART I
|
||||
|
ITEM 1.
|
Business
|
1
|
||
|
ITEM 1A.
|
Risk Factors
|
3
|
||
|
ITEM 2.
|
Properties
|
7
|
||
|
ITEM 3.
|
Legal Proceedings
|
7
|
||
|
ITEM 4.
|
Mine Safety Disclosures
|
7
|
||
|
PART II
|
||||
|
ITEM 5.
|
Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
|
7
|
||
|
ITEM 6.
|
Selected Financial Data
|
8
|
||
|
ITEM 7.
|
Management’s Discussion and Analysis of Financial Condition and Results of Operation
|
8
|
||
|
ITEM 7A.
|
Quantitative and Qualitative Disclosures About Market Risk
|
11
|
||
|
ITEM 8.
|
Financial Statements and Supplementary Data
|
F-1
|
||
|
ITEM 9.
|
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
|
12
|
||
|
ITEM 9A.
|
Controls and Procedures
|
12
|
||
|
PART III
|
||||
|
ITEM 10.
|
Directors, Executive Officers and Corporate Governance
|
12
|
||
|
ITEM 11.
|
Executive Compensation
|
14
|
||
|
ITEM 12.
|
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
|
15
|
||
|
ITEM 13.
|
Certain Relationships and Related Transactions, and Director Independence
|
15
|
||
|
ITEM 14.
|
Principal Accounting Fees and Services
|
16
|
||
|
PART IV
|
||||
|
ITEM 15.
|
Exhibits, Financial Statement Schedules
|
17
|
||
|
SIGNATURES
|
18
|
|||
|
·
|
Men’s Health
|
|
·
|
Women’s Health
|
|
·
|
Anti-Aging
|
|
·
|
General Health
|
|
·
|
Live 1-on-1 chats with Doctors
|
|
·
|
Sexual Health
|
|
·
|
Herbal Supplements
|
|
·
|
Nutritional Supplements
|
|
·
|
Pharmacy
|
|
Contents
|
Page(s)
|
|
Report of Independent Registered Public Accounting Firm
|
F-2
|
|
Balance Sheets at March 31, 2012 and 2011
|
F-3
|
|
Statements of Operations for the Fiscal Year Ended March 31, 2012 and 2011, and for the Period from September 29, 2010 (Inception) through March 31, 2012
|
F-4
|
|
Statement of Stockholders’ Equity (Deficit) for the Period from September 29, 2010 (Inception) through March 31, 2012
|
F-5
|
|
Statements of Cash Flows for the Fiscal Year Ended March 31, 2012 and 2011, and for the Period from September 29, 2010 (Inception) through March 31, 2012
|
F-6
|
|
Notes to the Financial Statements
|
F-7
|
|
Health Directory, Inc.
|
||||||||
|
(A Development Stage Company)
|
||||||||
|
Balance Sheets
|
|
March 31, 2012
|
March 31, 2011
|
|||||||
|
Assets
|
||||||||
|
Current assets
|
||||||||
|
Cash
|
$ | 7,813 | $ | 25,000 | ||||
|
Stock subscriptions receivable
|
- | 13,070 | ||||||
|
Total current assets
|
7,813 | 38,070 | ||||||
|
Total assets
|
$ | 7,813 | $ | 38,070 | ||||
|
Liabilities and stockholders' equity (deficit)
|
||||||||
|
Current liabilities:
|
||||||||
|
Accrued expenses
|
$ | 23,706 | $ | 7,175 | ||||
|
Total current liabilities
|
23,706 | 7,175 | ||||||
|
Total Liabilities
|
23,706 | 7,175 | ||||||
|
Stockholders' equity (deficit)
|
||||||||
|
Preferred stock: $0.001 par value: 10,000,000 shares authorized;
|
||||||||
|
none issued or outstanding
|
- | - | ||||||
|
Common stock: $0.001 par value: 500,000,000 shares authorized;
|
||||||||
|
3,759,400 and 2,759,400 shares issued and outstanding, respectively
|
3,759 | 2,759 | ||||||
|
Additional paid-in capital
|
86,311 | 37,311 | ||||||
|
Deficit accumulated during the development stage
|
(105,963 | ) | (9,175 | ) | ||||
|
Total stockholders' equity (deficit)
|
(15,893 | ) | 30,895 | |||||
|
Total liabilities and stockholders' equity (deficit)
|
$ | 7,813 | $ | 38,070 | ||||
|
See accompanying notes to the financial statements.
|
||||||||
|
Health Directory, Inc.
|
|
(A Development Stage Company)
|
|
Statements of Operations
|
|
For the Fiscal Year
Ended
|
For the Period from
September 29, 2010
|
For the Period from
September 29, 2010
|
||||||||||
|
March 31, 2012
|
March 31, 2011
|
March 31, 2012
|
||||||||||
|
Revenues
|
$ | - | $ | - | $ | - | ||||||
|
Operating expenses
|
||||||||||||
|
General and administrative expenses
|
1,485 | - | 1,485 | |||||||||
|
Professional fees
|
39,803 | 7,175 | 46,978 | |||||||||
|
Compensation - officer
|
55,500 | 2,000 | 57,500 | |||||||||
|
Total operating expenses
|
96,788 | 9,175 | 105,963 | |||||||||
|
Loss before taxes
|
(96,788 | ) | (9,175 | ) | (105,963 | ) | ||||||
|
Income tax provision
|
- | - | - | |||||||||
|
Net loss
|
$ | (96,788 | ) | $ | (9,175 | ) | $ | (105,963 | ) | |||
|
Net loss per common share:
|
||||||||||||
|
- Basic and diluted
|
$ | (0.03 | ) | $ | (0.00 | ) | ||||||
|
Weighted average common shares outstanding
|
||||||||||||
|
- basic and diluted
|
3,090,000 | 2,209,757 | ||||||||||
|
See accompanying notes to the financial statements.
|
||||||||||||
|
Common Stock, $0.001 Par Value
|
Additional
|
Deficit
Accumulated
during the
|
Total
|
|||||||||||||||||
|
Number of
Shares
|
Amount
|
Paid-in
Capital
|
Development Stage
|
Stockholders'
Equity
|
||||||||||||||||
|
Balance, September 29, 2010 (inception)
|
2,000,000 | $ | 2,000 | $ | - | $ | - | $ | 2,000 | |||||||||||
|
Contribution to capital
|
- | 100 | - | 100 | ||||||||||||||||
|
Shares issued at $0.05 per share for cash
|
||||||||||||||||||||
|
from December 1, 2010 through March 31, 2011
|
759,400 | 759 | 37,211 | - | 37,970 | |||||||||||||||
|
Net loss
|
(9,175 | ) | (9,175 | ) | ||||||||||||||||
|
Balance, March 31, 2011
|
2,759,400 | 2,759 | 37,311 | (9,175 | ) | 30,895 | ||||||||||||||
|
Shares issued to officer for compensation valued
|
||||||||||||||||||||
|
at $0.05 per share on December 1, 2011
|
1,000,000 | 1,000 | 49,000 | 50,000 | ||||||||||||||||
|
Net loss
|
(96,788 | ) | (96,788 | ) | ||||||||||||||||
|
Balance, March 31, 2012
|
3,759,400 | $ | 3,759 | $ | 86,311 | $ | (105,963 | ) | $ | (15,893 | ) | |||||||||
|
For the Fiscal Year
Ended
|
For the Period from
September 29, 2010
|
For the Period from
September 29, 2010
|
||||||||||
|
March 31, 2012
|
March 31, 2011
|
March 31, 2012
|
||||||||||
|
Cash flows from operating activities:
|
||||||||||||
|
Net loss
|
$ | (96,788 | ) | $ | (9,175 | ) | $ | (105,963 | ) | |||
|
Adjustments to reconcile net loss to net cash used in operating activities:
|
||||||||||||
|
Common share issued for compensation
|
50,000 | 2,000 | 52,000 | |||||||||
|
Changes in operating assets and liabilities:
|
||||||||||||
|
Accrued expenses
|
16,531 | 7,175 | 23,706 | |||||||||
|
Net cash used in operating activities
|
(30,257 | ) | - | (30,257 | ) | |||||||
|
Cash flows from financing activities:
|
||||||||||||
|
Captial contribution
|
- | 100 | 100 | |||||||||
|
Collection of stock subscription receivable
|
13,070 | - | 13,070 | |||||||||
|
Proceeds from sale of common stock
|
- | 24,900 | 24,900 | |||||||||
|
Net cash provided by financing activities
|
13,070 | 25,000 | 38,070 | |||||||||
|
Net change in cash
|
(17,187 | ) | 25,000 | 7,813 | ||||||||
|
Cash, beginning of period
|
25,000 | - | - | |||||||||
|
Cash, end of period
|
$ | 7,813 | $ | 25,000 | $ | 7,813 | ||||||
|
Supplemental disclosure of cash flows information:
|
||||||||||||
|
Interest aid
|
$ | - | $ | - | $ | - | ||||||
|
Income tax paid
|
$ | - | $ | - | $ | - | ||||||
|
Level 1
|
Quoted market prices available in active markets for identical assets or liabilities as of the reporting date.
|
|
|
Level 2
|
Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date.
|
|
|
Level 3
|
Pricing inputs that are generally observable inputs and not corroborated by market data.
|
|
●
|
Expected term of share options and similar instruments: The expected life of options and similar instruments represents the period of time the option and/or warrant are expected to be outstanding. Pursuant to Paragraph 718-10-50-2 of the FASB Accounting Standards Codification the expected term of share options and similar instruments represents the period of time the options and similar instruments are expected to be outstanding taking into consideration of the contractual term of the instruments and employees’ expected exercise and post-vesting employment termination behavior into the fair value (or calculated value) of the instruments. The Company uses historical data to estimate employee termination behavior. The contractual term of share options or similar instruments is used as expected term of share options or similar instruments for the Company if it is a newly formed corporation.
|
|
●
|
Expected volatility of the entity’s shares and the method used to estimate it. An entity that uses a method that employs different volatilities during the contractual term shall disclose the range of expected volatilities used and the weighted-average expected volatility. A thinly-traded or nonpublic entity that uses the calculated value method shall disclose the reasons why it is not practicable for the Company to estimate the expected volatility of its share price, the appropriate industry sector index that it has selected, the reasons for selecting that particular index, and how it has calculated historical volatility using that index. The Company uses the average historical volatility of the comparable companies over the expected contractual life of the share options or similar instruments as its expected volatility. If shares of a company are thinly traded the use of weekly or monthly price observations would generally be more appropriate than the use of daily price observations as the volatility calculation using daily observations for such shares could be artificially inflated due to a larger spread between the bid and asked quotes and lack of consistent trading in the market.
|
|
●
|
Expected annual rate of quarterly dividends. An entity that uses a method that employs different dividend rates during the contractual term shall disclose the range of expected dividends used and the weighted-average expected dividends. The expected dividend yield is based on the Company’s current dividend yield as the best estimate of projected dividend yield for periods within the expected contractual life of the option and similar instruments.
|
|
●
|
Risk-free rate(s). An entity that uses a method that employs different risk-free rates shall disclose the range of risk-free rates used. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods within the contractual life of the option and similar instruments.
|
|
March 31,
2012
|
March 31,
2011
|
|||||||
|
Net deferred tax assets – non-current:
|
||||||||
|
Expected income tax benefit from NOL carry-forwards
|
$
|
36,027
|
$
|
3,120
|
||||
|
Less valuation allowance
|
(36,027
|
)
|
(3,120
|
)
|
||||
|
Deferred tax assets, net of valuation allowance
|
$
|
-
|
$
|
-
|
||||
|
For the Fiscal Year Ended
March 31, 2012
|
For the Fiscal Year Ended March 31, 2011
|
|||||||
|
Federal statutory income tax rate
|
34.0
|
%
|
34.0
|
%
|
||||
|
Change in valuation allowance on net operating loss carry-forwards
|
(34.0
|
)
|
(34.0
|
)
|
||||
|
Effective income tax rate
|
0.0
|
%
|
0.0
|
%
|
||||
|
Name
|
Age
|
Position
|
|
Humaira Haider
|
41
|
Chief Executive Officer, President, Chief Financial Officer, Secretary, Treasurer and Director
|
|
·
|
been convicted in a criminal proceeding or been subject to a pending criminal proceeding (excluding traffic violations and other minor offenses);
|
|
·
|
had any bankruptcy petition filed by or against the business or property of the person, or of any partnership, corporation or business association of which he was a general partner or executive officer, either at the time of the bankruptcy filing or within two years prior to that time;
|
|
·
|
been subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction or federal or state authority, permanently or temporarily enjoining, barring, suspending or otherwise limiting, his involvement in any type of business, securities, futures, commodities, investment, banking, savings and loan, or insurance activities, or to be associated with persons engaged in any such activity;
|
|
·
|
been found by a court of competent jurisdiction in a civil action or by the Securities and Exchange Commission or the Commodity Futures Trading Commission to have violated a federal or state securities or commodities law, and the judgment has not been reversed, suspended, or vacated;
|
|
·
|
been the subject of, or a party to, any federal or state judicial or administrative order, judgment, decree, or finding, not subsequently reversed, suspended or vacated (not including any settlement of a civil proceeding among private litigants), relating to an alleged violation of any federal or state securities or commodities law or regulation, any law or regulation respecting financial institutions or insurance companies including, but not limited to, a temporary or permanent injunction, order of disgorgement or restitution, civil money penalty or temporary or permanent cease-and-desist order, or removal or prohibition order, or any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or
|
|
·
|
been the subject of, or a party to, any sanction or order, not subsequently reversed, suspended or vacated, of any self-regulatory organization (as defined in Section 3(a)(26) of the Exchange Act), any registered entity (as defined in Section 1(a)(29) of the Commodity Exchange Act), or any equivalent exchange, association, entity or organization that has disciplinary authority over its members or persons associated with a member.
|
|
Name and Principal Position
|
Year
|
Salary ($)
|
Bonus ($)
|
Stock
Awards ($)
|
Option
Awards ($)
|
Non-Equity Incentive Plan Compensation ($)
|
Non-Qualified Deferred Compensation Earnings ($)
|
All Other Compensation ($)
|
Totals ($)
|
|||||||||||||||||||||||||
|
Humaira Haider, President,
Chief Financial Officer, Treasurer, Secretary, Director
|
2011
|
$
|
5,500
|
0
|
$
|
0
|
|
0
|
0
|
0
|
0
|
$
|
5,500
|
|||||||||||||||||||||
|
Name
|
|
|
Number of Shares Beneficially Owned
|
|
|
Percent of Class (1)
|
|
|
Humaira Haider
|
3,000,000
|
79.8%
|
|||||
|
5806 Falls Gate Court
|
|||||||
|
Falls Church, VA 22041
|
|||||||
|
All Executive Officers and Directors as a group (1 person)
|
|
|
3,000,000
|
|
|
79.8%
|
|
(1) Based on
3,759,400
shares of common stock outstanding as of June 28, 2012
|
|
(A)
|
Any of our directors or officers;
|
|
|
(B)
|
Any proposed nominee for election as our director;
|
|
|
(C)
|
Any person who beneficially owns, directly or indirectly, shares carrying more than 10% of the voting rights attached to our common stock; or
|
|
|
(D)
|
Any relative or spouse of any of the foregoing persons, or any relative of such spouse, who has the same house as such person or who is a director or officer of any parent or subsidiary of our company.
|
|
·
|
the director is, or at any time during the past three years was, an employee of the company;
|
|
·
|
the director or a family member of the director accepted any compensation from the company in excess of $120,000 during any period of 12 consecutive months within the three years preceding the independence determination (subject to certain exclusions, including, among other things, compensation for board or board committee service);
|
|
·
|
a family member of the director is, or at any time during the past three years was, an executive officer of the company;
|
|
·
|
the director or a family member of the director is a partner in, controlling stockholder of, or an executive officer of an entity to which the company made, or from which the company received, payments in the current or any of the past three fiscal years that exceed 5% of the recipient’s consolidated gross revenue for that year or $200,000, whichever is greater (subject to certain exclusions);
|
|
·
|
the director or a family member of the director is employed as an executive officer of an entity where, at any time during the past three years, any of the executive officers of the company served on the compensation committee of such other entity; or the director or a family member of the director is a current partner of the company’s outside auditor, or at any time during the past three years was a partner or employee of the company’s outside auditor, and who worked on the company’s audit.
|
|
Years Ended March 31,
|
||||||||
|
Category
|
2012
|
2011
|
||||||
|
Audit Fees
|
$ | 7,000 | $ | 5,000 | ||||
|
Audit Related Fees
|
0 | 0 | ||||||
|
Tax Fees
|
0 | 0 | ||||||
|
All Other Fees
|
0 | 0 | ||||||
|
·
|
approved by our audit committee; or
|
|
·
|
entered into pursuant to pre-approval policies and procedures established by the audit committee, provided the policies and procedures are detailed as to the particular service, the audit committee is informed of each service, and such policies and procedures do not include delegation of the audit committee's responsibilities to management.
|
|
Exhibit No.
|
Title of Document
|
|
31.1
|
Rule 13a-14(a)/ 15d-14(a) Certification of Chief Executive Officer
|
|
32.1
|
Section 1350 Certification of Chief Executive Officer
|
|
Exhibit No.
|
Title of Document
|
|
3.1
|
Articles of Incorporation
(2)
|
|
3.2
|
By-Laws
(1)
|
|
10.1
|
Employment agreement with Humaira Haider, dated May 1, 2011
(1)
|
|
31.1*
|
Certification of Humaira Haider pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
|
32.1**
|
Certification of the Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
|
|
101.INS **
|
XBRL Instance Document
|
|
101.SCH **
|
XBRL Taxonomy Extension Schema Document
|
|
101.CAL **
|
XBRL Taxonomy Extension Calculation Linkbase Document
|
|
101.DEF **
|
XBRL Taxonomy Extension Definition Linkbase Document
|
|
101.LAB **
|
XBRL Taxonomy Extension Label Linkbase Document
|
|
101.PRE **
|
XBRL Taxonomy Extension Presentation Linkbase Document
|
|
(1)
|
Incorporated by reference to Form S-1 filed with the SEC on May 27, 2011.
|
|
(2)
|
Incorporated by reference to Amendment No. 1 to the Form S-1/A filed with the SEC on July 14, 2011.
|
|
*
|
Filed herewith.
|
|
**
|
In accordance with SEC Release 33-8238, Exhibit 32.1 is being furnished and not filed. XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.
|
|
HEALTH DIRECTORY, INC.
|
|||
|
Date: June 29, 2012
|
By:
|
/s/
Humaira Haider
|
|
|
Name:
|
Humaira Haider
|
||
|
Title:
|
Name: Humaira Haider
Position: President,
Principal Executive Officer,
Principal Financial Officer
Principal Accounting Officer, Director
|
||
|
Name
|
Title
|
Date
|
|
| /s/ Humaira Haider | President, Chief Financial Officer, Secretary and Director |
June 29, 2012
|
|
|
Humaira Haider
|
(Principal Executive Officer)
|
||
|
(Principal Financial and Accounting Officer)
|
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|